EGFR and cancer: A survey of the literature provided a biochemical mechanism consistent with the modeled simulations insofar as sialylation can disrupt the galectin lattice, which in turn can influence EGFR activity in cancer [45] as depicted in Figure 4 and described in more detail in the Discussion, below.